Close
Digital Health & Ai Innovation summit 2026
APE 2026

Microchip has become new technology to detect type and severity of cancer

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Supplier Quality Management in Complex Pharma...

Overseeing the intricate web of global providers for raw materials and contract services is essential for ensuring product safety and maintaining a resilient pharmaceutical supply chain in a volatile market.

GMP Audits Driving Continuous Quality Excellence

Far from being mere regulatory hurdles, internal and external Good Manufacturing Practice assessments serve as vital catalysts for institutional growth and the pursuit of operational perfection in pharmaceutical production.

Digital Quality Systems Transforming Compliance Models

The transition from manual quality assurance to integrated digital platforms is redefining how pharmaceutical and medical device companies maintain regulatory readiness and operational agility.

Scientists at the University of Toronto have developed a chip that can detect the type and severity of cancer, a breakthrough that will hopefully enable doctors to treat the disease earlier. Based on nanowires, the chip can detect the signature biomarkers that indicate the presence of cancer at the cellular level. These biomolecules—genes that indicate aggressive or benign forms of the disease and differentiate subtypes of the cancer—are generally present only at low levels in biological samples.

The researchers said the new device can sense the biomarkers that indicate the presence of cancer at the cellular level, generally present only at low levels in biological samples. Analysis can be completed in 30 minutes, using a handheld device such as a Blackberry made by Research In Motion Ltd. Of Waterloo, Ontario, Canada.

Lead investigator Shana Kelley, a professor in the Leslie Dan Faculty of Pharmacy and the Faculty of Medicine, said in an interview, This could change the way we do screening, we could do a lot more screening in the future.

The team’s microchip platform has been tested on prostate cancer and head and neck cancer models. In addition, it could potentially be used to diagnose and assess other cancers and infectious diseases, such as HIV, MRSA, and H1N1 flu.

The chip is about the size of a person’s fingertip, she said. The chip, combined with the handheld device would replace the room of computers now needed to evaluate a sample of cancer biomarkers, Kelley said.

Kelley worked with University of Toronto engineering professor Ted Sargent and a team from Princess Margaret Hospital and Queen’s University in Kingston, Ontario.

Latest stories

Related stories

Supplier Quality Management in Complex Pharma Networks

Overseeing the intricate web of global providers for raw materials and contract services is essential for ensuring product safety and maintaining a resilient pharmaceutical supply chain in a volatile market.

GMP Audits Driving Continuous Quality Excellence

Far from being mere regulatory hurdles, internal and external Good Manufacturing Practice assessments serve as vital catalysts for institutional growth and the pursuit of operational perfection in pharmaceutical production.

Digital Quality Systems Transforming Compliance Models

The transition from manual quality assurance to integrated digital platforms is redefining how pharmaceutical and medical device companies maintain regulatory readiness and operational agility.

Advancing Data Integrity Across Biotech Manufacturing

Ensuring the accuracy and reliability of information is the lifeblood of biotechnology production, where even minor discrepancies in digital or physical records can compromise product safety and regulatory standing.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »